---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-23-000120"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:49:52.673827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14

## Summary
- FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.
- FY2024 adjusted diluted EPS guidance $2.05-$2.25; includes ~$0.40 dilution from Seagen.
- Cost realignment program now expected to deliver at least $4.0B annual net savings by end 2024.
- Excluding COVID products and Seagen, operational revenue growth 3%-5% YoY.
- Seagen acquisition has received all regulatory approvals; closing expected Dec 14, 2023.

## SEC filing metadata
- accession: 0000078003-23-000120
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/0000078003-23-000120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/pfe-20231213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-23-000120
- JSON: https://secwatch.observer/filing/0000078003-23-000120.json
- Plain text: https://secwatch.observer/filing/0000078003-23-000120.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.